stockmarketproxy
/
ROIVNasdaq SEC EDGAR

Roivant Sciences Ltd.

Pharmaceutical Preparations·LONDON·FY end 03/31·CIK 1635088
OverviewFinancialsCompensationGovernanceInsidersFilings

Board of Directors

2 members · FY 2024
DirectorRoleTenureAgeCommitteesIndep.Annual fees
Matthew GlineCEO and Director41
Mayukh SukhatmeDirector49

Risk-factor diff

10-K Item 1A — YoY changes

Need at least two years of 10-K filings to compute. Will populate once both this year's and last year's 10-Ks have been ingested.

Policies & disclosures

Clawback, anti-hedging, stock ownership, and related-party policies will populate from extracted proxy sections.